Welcome to our dedicated page for Avicanna news (Ticker: AVCNF), a resource for investors and traders seeking the latest updates and insights on Avicanna stock.
Avicanna Inc. operates as a commercial-stage international biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products. Company updates cover R&D and clinical development for cannabinoid-based medicines, medical affairs initiatives, real-world evidence generated through MyMedi.ca, and formulation work involving PwdRx and Rho Phyto. Updates also address regulatory developments affecting medical cannabis research and patient access.
Commercial developments include manufacturing, product launches, exports and partnerships through Avicanna LATAM SAS and Santa Marta Golden Hemp SAS, including Aureus-branded products and CBD wellness topicals. Announcements also report audited financial results, board changes, clinical symposium programming and the expansion of proprietary evidence-based products across medical and pharmaceutical markets.
Avicanna (OTCQX: AVCNF) reported Q1 2026 record revenue of $6.68 million, up about 6% year-over-year, and gross profit of $3.84 million with a 58% gross margin. Adjusted EBITDA was a $0.15 million loss, while the working capital deficit improved to $0.32 million.
Canadian commercial growth included higher MyMedi.ca unit sales and proprietary product expansion. Avicanna also highlighted real-world evidence pain study results, initiation of a Phase I THC dose-finding trial, and SMGH’s first commercial organic flower export to Australia.
Avicanna (OTCQX: AVCNF) welcomed the U.S. Department of Justice and DEA rescheduling of certain cannabinoid-based products from Schedule I to Schedule III on April 28, 2026, and provided a scientific update. The company noted progress across clinical programs, including a Phase I dose-finding study and initial Phase II arthritic pain enrollment, advancement of the QUIX™ nanotechnology delivery platform, and expanded medical affairs and education initiatives.
Avicanna said it will monitor U.S. regulatory developments and assess FDA-aligned pathways, strategic partnerships, and licensing to support potential future U.S. market entry.
Avicanna (OTCQX: AVCNF) will hold its 6th Annual Clinical Symposium on Cannabinoid Therapeutics, “From Emerging Evidence to Clinical Practice,” on June 11–12, 2026 at MaRS Discovery District in Toronto and virtually. The two-day program features clinical workshops, new research, case discussions, and multidisciplinary panels across pain, neurology, psychiatry, women’s health, and veterans’ care.
Sessions will be recorded and added to the Avicenna Academy; clinicians may register or submit posters for consideration.
Avicanna (OTCQX: AVCNF) announced a board change effective April 1, 2026: John McVicar resigned and Ozgur Kilic was appointed to the Board of Directors. Mr. Kilic brings more than 20 years of senior finance and operational experience across global pharma companies.
The company said Mr. Kilic holds dual bachelor degrees and an MBA, plus ACMA and CGMA designations, and intends to support Avicanna’s planned U.S. expansion and international growth while contributing to its pharmaceutical pipeline and commercial portfolio.
Avicanna (OTCQX: AVCNF) reported audited full year 2025 results showing stable revenue of $25.48M, expanded gross margin to 53%, and positive adjusted EBITDA of $0.31M in Q4 2025 while achieving near break-even adjusted EBITDA of $(0.29)M for the year.
Highlights include 27% growth in proprietary SKUs, 32% growth in listings, initiation of a blinded Phase II osteoarthritis RCT with UHN, promising preclinical absorption gains for the PwdRx platform, a provisional patent filing, and first commercial exports to Switzerland and Australia.
Avicanna (OTCQX: AVCNF) announced publication of an investigator-led prospective observational Medical Cannabis Real-World Evidence study in the Canadian Journal of Pain.
The 24-week study of physician-authorized medical cannabis reported statistically significant improvements in pain interference, pain intensity, anxiety, depressive symptoms, and quality of life, though changes did not meet minimal clinically important difference thresholds. The study remains ongoing with continued enrollment across seven Canadian provinces.
Avicanna (OTCQX: AVCNF) welcomed the December 19, 2025 executive order to reclassify cannabis from Schedule I to Schedule III and provided a scientific update on 2025 R&D, clinical development, and medical affairs progress.
Key highlights include a real-world evidence study with University Health Network that has enrolled approximately 450 patients, the start of a Phase II randomized controlled trial for arthritic pain in December 2025, a newly granted USPTO patent, and translation of proprietary technologies including PwdRx into commercial stage, plus expanded medical affairs and patient-access initiatives.
Avicanna (OTCQX: AVCNF), through its subsidiary Santa Marta Golden Hemp SAS (SMGH), has completed its first export of non-psychoactive CBD dominant cannabis flower to Switzerland. This milestone marks SMGH's first organic certified flower export and represents the 20th international market for Aureus-branded products and 23rd market for all Avicanna products.
The export follows the company's 2024 infrastructure and practice improvements at SMGH, aimed at expanding its Aureus-branded premium organic flower portfolio. The shipment included three proprietary cannabis varieties registered in Colombia, targeting growing demand in European and Australian medical cannabis markets.
Avicanna LATAM SAS (OTC:AVCNF) has partnered with Harrington Wellness to launch re+PLAY CBD wellness brand topicals across the United States. The collaboration introduces two initial products: a 3% CBD localized cream and a 2% CBD and 1% CBG transdermal gel utilizing Avicanna's patented deep tissue technology.
The products, developed through collaboration between scientists, athletes, doctors, and certified athletic trainers, will be available through replaycbd.com and select U.S. retailers in September 2025. The CBD and CBG ingredients are sourced from USDA organic certified hemp cultivated by Avicanna's subsidiary Santa Marta Golden Hemp and manufactured in Colombia.
Avicanna (AVCNF) reported strong financial results for 2024, with revenue reaching $25.5 million, marking a 52% increase from 2023. The company achieved significant improvements in profitability, with gross profits rising 94% to $12.9 million and gross margins expanding to 51%.
Key operational highlights include the initiation of a 1,000-patient medical cannabis study, expansion to 42 proprietary commercial SKUs, and completion of several clinical studies, including research on epidermolysis bullosa and musculoskeletal pain. The company's adjusted EBITDA loss narrowed by 68% to $1.4 million, and they successfully repaid $1.3 million in debentures.
Notable achievements include obtaining drug registration in Colombia for Trunerox™, delivering proprietary topical products to a multinational pharmaceutical company, and securing two new US patents for their cannabinoid delivery technologies.